Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares MSCI China ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares MSCI China ETF trades at $51.22 (market cap $5.82B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares MSCI China ETF for 65 Days on average.
| GMED | MCHI | |
|---|---|---|
Market Cap | $10.25B | $5.82B |
Volume | 1,059,528 | 1,436,013 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $65.59 |
52-Week Low | $58.33 | $50.48 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MCHI, the iShares MSCI China ETF, trades at $52.135, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and weak domestic consumption, though corporate profits surged 26% in Q2. Recent news highlights potential trade developments from upcoming U.S.-China talks and concerns over export controls on AI and semiconductors.
The outlook remains cautious with significant discount to US indices offering potential value, but risks from global trade tensions and China's economic rebalancing persist. Institutional activity shows mixed positioning, with some funds increasing stakes while others reduce exposure, reflecting uncertainty in Chinese equity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
